Expert Recommendations for the Diagnosis, Treatment, and Management of Adult B-Cell Acute Lymphoblastic Leukemia in Latin America.

Abstract

PURPOSE:

Despite strong induction chemotherapy response rates, only 30%-40% of patients with adult B-cell acute lymphoblastic leukemia (ALL) attain long-term remission. This study analyzes ALL in Latin America (LA) and recommends diagnosis, treatment, and management protocols.

METHODS:

The Americas Health Foundation organized a panel of hematologists from Argentina, Brazil, Chile, Colombia, and Mexico to examine ALL diagnosis and therapy and produce recommendations.

RESULTS:

Lack of regional data, unequal access to diagnosis and therapy, inadequate treatment response, and uneven health care distribution complicate adult ALL management. The panel recommended diagnosis, first-line and refractory treatment, and post-transplantation maintenance. Targeted treatments, including rituximab, blinatumomab, and inotuzumab ozogamicin, are becoming available in LA and must be equitably accessed.

CONCLUSION:

This review adapts global information on treating ALL to LA. Governments, the medical community, society, academia, industry, and patient advocates must work together to improve policies.

• Authors: Ana Lisa Basquiera, Maria Cristina Seiwald, Carlos Roberto Best Aguilera, Leonardo Enciso, Isolda Fernandez, Angela Marie Jansen, Elenaide Nunes, Matias Sanchez Del Villar, Victor I Urbalejo Ceniceros, Vanderson Rocha
• Journal: JCO global oncology (JCO Glob Oncol) Vol. 9 Pg. e2200292 (05 2023) ISSN: 2687-8941 [Electronic] United States
• PMID: 37167576 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)

Chemical References

• Inotuzumab Ozogamicin
• Rituximab

Topics

• Humans
• Adult
• Latin America (epidemiology)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (therapy, drug therapy)
• Inotuzumab Ozogamicin (therapeutic use)
• Rituximab (therapeutic use)
• Mexico